Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
OMCL

OMCL - Omnicell Inc Stock Price, Fair Value and News

27.85USD+0.72 (+2.65%)Market Closed

Market Summary

OMCL
USD27.85+0.72
Market Closed
2.65%

OMCL Stock Price

View Fullscreen

OMCL RSI Chart

OMCL Valuation

Market Cap

1.3B

Price/Earnings (Trailing)

-62.77

Price/Sales (Trailing)

1.11

EV/EBITDA

11.81

Price/Free Cashflow

9.16

OMCL Price/Sales (Trailing)

OMCL Profitability

Operating Margin

82.70%

EBT Margin

-1.75%

Return on Equity

-1.71%

Return on Assets

-0.91%

Free Cashflow Yield

10.92%

OMCL Fundamentals

OMCL Revenue

Revenue (TTM)

1.1B

Rev. Growth (Yr)

-13.04%

Rev. Growth (Qtr)

-13.33%

OMCL Earnings

Earnings (TTM)

-20.4M

Earnings Growth (Yr)

49.4%

Earnings Growth (Qtr)

-358.87%

Breaking Down OMCL Revenue

Last 7 days

0.1%

Last 30 days

-4.7%

Last 90 days

-20.4%

Trailing 12 Months

-53.5%

How does OMCL drawdown profile look like?

OMCL Financial Health

Current Ratio

2.52

OMCL Investor Care

Shares Dilution (1Y)

2.06%

Diluted EPS (TTM)

-0.45

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20231.3B1.2B1.2B1.1B
20221.2B1.3B1.3B1.3B
2021914.4M987.5M1.1B1.1B
2020924.2M906.4M891.3M892.2M
2019807.2M835.9M860.5M897.0M
2018746.8M754.4M771.9M787.3M
2017673.5M681.6M691.6M712.7M
2016539.3M599.5M651.0M695.9M
2015455.4M463.1M475.8M484.6M
2014395.2M406.6M425.1M440.9M
2013337.0M355.3M365.0M380.6M
2012252.5M266.9M286.8M314.0M
2011225.4M231.7M239.9M245.5M
20100216.4M219.4M222.4M
2009000213.5M
Get all data in R, Python etc through our Historical Stock Data APIs
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Omnicell Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 15, 2024
manley corey j
sold (taxes)
-2,298
27.69
-83.00
evp&chief legal/admin officer
Mar 15, 2024
spears joseph brian
sold (taxes)
-1,550
27.69
-56.00
chief accounting officer & svp
Feb 27, 2024
lipps randall a
acquired
-
-
107,251
chairman, president and ceo
Feb 27, 2024
etta nchacha
acquired
-
-
37,853
evp & cfo
Feb 27, 2024
manley corey j
acquired
-
-
31,965
evp&chief legal/admin officer
Feb 15, 2024
spears joseph brian
sold (taxes)
-3,905
28.3
-138
chief accounting officer & svp
Jan 30, 2024
voynick eileen j.
acquired
-
-
2,426
-
Jan 30, 2024
scott bruce e
acquired
-
-
51.00
-
Dec 15, 2023
lipps randall a
sold (taxes)
-246,127
38.26
-6,433
chairman, president and ceo
Dec 15, 2023
manley corey j
sold (taxes)
-8,493
38.26
-222
evp&chief legal/admin officer

1–10 of 50

Which funds bought or sold OMCL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 25, 2024
NEW YORK STATE TEACHERS RETIREMENT SYSTEM
unchanged
-
-539,000
1,875,000
 -%
Apr 25, 2024
FIRST MERCHANTS CORP
sold off
-100
-257,310
-
 -%
Apr 25, 2024
Horrell Capital Management, Inc.
added
82.00
778,000
2,660,000
 0.74%
Apr 25, 2024
Lindbrook Capital, LLC
reduced
-92.59
-8,618
526
 -%
Apr 25, 2024
Zurcher Kantonalbank (Zurich Cantonalbank)
unchanged
-
-84,697
294,726
 -%
Apr 25, 2024
Bank of New York Mellon Corp
sold off
-100
-229,758
-
 -%
Apr 25, 2024
Bank of New York Mellon Corp
added
10.61
-6,177,420
37,685,100
 0.01%
Apr 25, 2024
Allworth Financial LP
reduced
-82.65
-13,512
2,105
 -%
Apr 25, 2024
SIMPLEX TRADING, LLC
sold off
-100
-121,000
-
 -%
Apr 24, 2024
Spire Wealth Management
reduced
-5.47
-1,027
5,554
 -%

1–10 of 47

Are Funds Buying or Selling OMCL?

Are funds buying OMCL calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own OMCL
No. of Funds

Unveiling Omnicell Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
12.25%
5,571,166
SC 13G/A
Jan 19, 2024
blackrock inc.
17.3%
7,887,234
SC 13G/A
Dec 11, 2023
wellington management group llp
0.26%
116,773
SC 13G/A
Sep 11, 2023
vanguard group inc
10.03%
4,532,732
SC 13G/A
Feb 09, 2023
vanguard group inc
9.92%
4,430,315
SC 13G/A
Feb 06, 2023
wellington management group llp
7.34%
3,277,600
SC 13G/A
Jan 23, 2023
blackrock inc.
12.8%
5,728,315
SC 13G/A
Feb 10, 2022
vanguard group inc
10.79%
4,740,493
SC 13G/A
Feb 04, 2022
wellington management group llp
5.76%
2,531,555
SC 13G/A
Jan 27, 2022
blackrock inc.
15.9%
6,983,442
SC 13G/A

Recent SEC filings of Omnicell Inc

View All Filings
Date Filed Form Type Document
Apr 11, 2024
ARS
ARS
Apr 04, 2024
DEF 14A
DEF 14A
Mar 19, 2024
4
Insider Trading
Mar 19, 2024
4
Insider Trading
Feb 29, 2024
8-K
Current Report
Feb 29, 2024
4
Insider Trading
Feb 29, 2024
4
Insider Trading
Feb 29, 2024
4
Insider Trading
Feb 28, 2024
10-K
Annual Report
Feb 16, 2024
4
Insider Trading

Peers (Alternatives to Omnicell Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
UNH
456.6B
371.6B
 0.44% 0.97%
20.4
1.23
 14.64% 11.24%
CI
103.6B
195.3B
 -2.45% 41.59%
19.29
0.53
 8.17% -20.79%
CVS
84.5B
357.8B
 -15.42% -8.05%
10.12
0.24
 10.95% 93.52%
HCA
81.1B
65.0B
 -7.58% 8.53%
15.47
1.25
 7.86% -7.11%
CNC
39.7B
155.5B
 -5.58% 8.00%
14.51
0.26
 6.34% 84.42%
DVA
11.7B
12.1B
 -2.44% 51.70%
16.93
0.96
 4.57% 23.40%
UHS
11.5B
14.3B
 -8.81% 13.72%
16.01
0.8
 6.59% 6.24%
MID-CAP
CHE
8.5B
2.3B
 -13.21% 2.71%
31.02
3.73
 6.06% 9.17%
ACHC
6.8B
2.9B
 -6.00% 1.13%
-313.66
2.32
 12.20% -107.93%
AMN
2.2B
3.8B
 -7.09% -33.84%
10.27
0.57
 -27.73% -52.50%
AMEH
2.0B
1.4B
 -10.80% 1.66%
33.48
1.47
 21.19% 34.42%
SMALL-CAP
ADUS
1.5B
1.1B
 -8.94% -17.15%
24.52
1.45
 11.31% 35.83%
BKD
1.3B
3.0B
 5.61% 63.76%
-6.97
0.44
 6.74% 20.73%
BEAT
52.7M
-
 -9.91% -0.99%
-3.6
-
 - -12.94%
AMS
20.1M
21.3M
 17.84% 15.27%
37.65
0.94
 8.00% -62.25%

Omnicell Inc News

Latest updates
MarketBeat • 23 Apr 2024 • 08:52 am
Omnicell, Inc. (NASDAQ:OMCL) Given Average Rating of "Hold" by Brokerages
Simply Wall St • 18 Apr 2024 • 11:34 am
Shareholders in Omnicell (NASDAQ:OMCL) have lost 81%, as stock drops 4.3% this past week
Yahoo Finance • 27 Mar 2024 • 07:00 am
Reasons for the Decline of Omnicell (OMCL)
Yahoo Finance • 01 Mar 2024 • 08:00 am
Here's Why You Should Retain Omnicell (OMCL) Stock Now
Simply Wall St • 29 Feb 2024 • 08:00 am
Omnicell, Inc.'s (NASDAQ:OMCL) 25% Dip In Price Shows Sentiment Is Matching Revenues
American Banking and Market News • 2 months ago
Rhumbline Advisers Cuts Stock Position in Omnicell, Inc. (NASDAQ:OMCL)
Simply Wall St • 2 months ago
Is It Too Late To Consider Buying Omnicell, Inc. (NASDAQ:OMCL)?
Seeking Alpha • 2 months ago
Omnicell Is Building A Strong Moat (NASDAQ:OMCL)
Yahoo Finance • 2 months ago
Analysts Have Been Trimming Their Omnicell, Inc. (NASDAQ:OMCL) Price Target After Its Latest Report
Yahoo Finance • 3 months ago
Here's Why You Should Retain Omnicell (OMCL) Stock Now

Omnicell Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-13.3%259299299291298348331319311296273252249214200230248229217203212
Gross Profit-20.1%10513213412512215915815014914713612212497.0083.0011012411210497.00102
Operating Expenses0.4%12912812714816014114614513811710710310387.0090.0097.0010188.0085.0084.0083.00
  S&GA Expenses-1.9%10210410412513211511912011698.0089.0087.0088.0071.0069.0079.0082.0071.0068.0068.0066.00
  R&D Expenses10.5%27.0024.0023.0023.0028.0025.0026.0025.0022.0019.0018.0016.0015.0015.0021.0019.0019.0017.0017.0016.0017.00
EBITDA Margin-0.06*-0.05*0.05*0.07*0.10*0.10*0.11*0.12*0.13*0.13*0.11*0.10*--------
Income Taxes-326.5%-4.142.009.00-6.18-7.101.002.00-3.24-7.18-5.993.00-1.21-2.502.00-2.520.00-0.123.001.008.002.00
Earnings Before Taxes-350.8%-18.527.0012.00-21.18-35.5117.0011.005.007.0023.0023.0013.0014.0011.00-6.8211.0022.0023.0017.0011.0017.00
EBT Margin44.0%-0.02*-0.03*-0.02*-0.02*0.00*0.03*0.04*0.05*0.06*0.07*0.06*0.03*---------
Net Income-358.9%-14.376.003.00-15.00-28.4117.009.008.0014.0029.0020.0014.0016.009.00-4.3011.0022.0020.0016.003.0015.00
Net Income Margin38.8%-0.02*-0.03*-0.02*-0.01*0.00*0.04*0.05*0.06*0.07*0.07*0.06*0.04*---------
Free Cashflow-36.7%29.0046.0061.003.0068.008.00-19.16-27.4849.0036.0066.0052.00---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets0.2%2,2272,2222,1942,2512,2112,1802,1312,1232,1422,0511,9611,8871,8251,7191,2221,2321,2411,2441,1971,1771,081
  Current Assets1.5%928914881935882849788776781889984904829963465478483477430414397
    Cash Equivalents4.7%46844739934033026624526534948261454849062913410412713787.0077.0067.00
  Inventory-5.2%11011613114114814715013712010410196.0096.00103114113108106104104101
  Net PPE1.6%10910710398.0094.0088.0082.0077.0071.0065.0062.0061.0059.0058.0058.0053.0054.0055.0053.0052.0052.00
  Goodwill0.2%736734736735734731734740739616499499499160335335337335336336336
Liabilities0.4%1,0381,0341,0301,1081,0811,0441,0391,048996940908876857801335353396437424447402
  Current Liabilities-0.4%368369370454428377374951876339317292276234237248237228211211205
  Long Term Debt-----------------50.0077.0077.0097.00135
    LT Debt, Current----------------------
    LT Debt, Non Current-----------------50.0077.0077.0097.00135
Shareholder's Equity0.1%1,1891,1871,1641,1431,1301,1351,0931,0751,1471,1111,0531,011968918887879845808773730680
  Retained Earnings-3.7%370385379376391419402393369355325305291274266270259237217201197
  Additional Paid-In Capital1.1%1,1221,1101,0891,0731,0471,0319989831,0251,003971950920892821808781770753725678
Shares Outstanding0.2%46.0045.0045.0045.0045.0044.0044.0044.0043.0043.0043.0043.00---------
Float---3,300---5,000---6,500---3,000---3,500--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-32.6%38,41457,00772,90312,77082,15321,175-9,551-15,99659,63242,98971,77357,41576,44836,68747,50425,23134,82056,42827,26326,49747,452
  Share Based Compensation-18.7%12,18714,98214,08914,04217,51617,31017,21316,20814,68313,66613,03911,77211,66311,02411,35110,6598,8748,5058,2608,4108,034
Cashflow From Investing12.8%-12,372-14,187-14,817-13,640-17,252-15,867-6,817-18,733-192,385-193,631-13,350-13,132-236,692-9,961-19,438-13,775-14,903-14,811-15,253-16,697-12,902
Cashflow From Financing364.8%13,1302,8253,6033,8623,5629,056-1,452-32,1196,66618,2846,81415,59920,399468,1781,458-33,766-30,5248,628-1,405-178-10,678
  Buy Backs--------52,210-----53,035-------

OMCL Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues$ 1,147,112$ 1,295,947$ 1,132,018
Cost of revenues650,272706,960577,365
Gross profit496,840588,987554,653
Operating expenses:   
Research and development97,115104,96975,716
Selling, general, and administrative434,593486,341389,430
Total operating expenses531,708591,310465,146
Income (loss) from operations(34,868)(2,323)89,507
Interest and other income (expense), net14,760(130)(23,500)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Total(20,108)(2,453)66,007
Provision for (benefit from) income taxes263(8,101)(11,842)
Net income (loss)$ (20,371)$ 5,648$ 77,849
Net income (loss) per share:   
Basic (in dollars per share)$ (0.45)$ 0.13$ 1.79
Diluted (in dollars per share)$ (0.45)$ 0.12$ 1.62
Weighted-average shares outstanding:   
Basic (in shares)45,21244,39843,475
Diluted (in shares)45,21245,89147,943
Product revenues   
Revenues$ 708,561$ 903,222$ 812,512
Cost of revenues414,106493,626422,855
Services and other revenues   
Revenues438,551392,725319,506
Cost of revenues$ 236,166$ 213,334$ 154,510

OMCL Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
shares in Thousands, $ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 467,972$ 330,362
Accounts receivable and unbilled receivables, net of allowances of $5,564 and $5,153, respectively252,025299,469
Inventories110,099147,549
Prepaid expenses25,96627,070
Other current assets71,50977,362
Total current assets927,571881,812
Property and equipment, net108,60193,961
Long-term investment in sales-type leases, net42,95432,924
Operating lease right-of-use assets24,98838,052
Goodwill735,810734,274
Intangible assets, net211,173242,906
Long-term deferred tax assets32,90122,329
Prepaid commissions52,41459,483
Other long-term assets90,466105,017
Total assets2,226,8782,210,758
Current liabilities:  
Accounts payable45,02863,389
Accrued compensation51,75473,455
Accrued liabilities149,276172,655
Deferred revenues, net121,734118,947
Total current liabilities367,792428,446
Long-term deferred revenues58,62237,385
Long-term deferred tax liabilities1,6202,095
Long-term operating lease liabilities33,91039,405
Other long-term liabilities6,3186,719
Convertible senior notes, net569,662566,571
Total liabilities1,037,9241,080,621
Commitments and contingencies (Note 14)
Stockholders’ equity:  
Preferred stock, $0.001 par value, 5,000 shares authorized; no shares issued00
Common stock, $0.001 par value, 100,000 shares authorized; 55,822 and 55,030 shares issued; 45,539 and 44,747 shares outstanding, respectively5655
Treasury stock at cost, 10,283 shares outstanding, respectively(290,319)(290,319)
Additional paid-in capital1,122,2921,046,760
Retained earnings370,357390,728
Accumulated other comprehensive loss(13,432)(17,087)
Total stockholders’ equity1,188,9541,130,137
Total liabilities and stockholders’ equity$ 2,226,878$ 2,210,758
Treasury stock, shares outstanding (in shares)10,28310,283

About Omnicell Inc

OMCL
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Santa Clara, California.
 CEO
 WEBSITEomnicell.com
 INDUSTRYHealthcare Plans
 EMPLOYEES3780

Omnicell Inc Frequently Asked Questions

What is the ticker symbol for Omnicell Inc? What does OMCL stand for in stocks?

OMCL is the stock ticker symbol of Omnicell Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Omnicell Inc (OMCL)?

As of Fri Apr 26 2024, market cap of Omnicell Inc is 1.28 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OMCL stock?

You can check OMCL's fair value in chart for subscribers.

What is the fair value of OMCL stock?

You can check OMCL's fair value in chart for subscribers. The fair value of Omnicell Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Omnicell Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OMCL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Omnicell Inc a good stock to buy?

The fair value guage provides a quick view whether OMCL is over valued or under valued. Whether Omnicell Inc is cheap or expensive depends on the assumptions which impact Omnicell Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OMCL.

What is Omnicell Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, OMCL's PE ratio (Price to Earnings) is -62.77 and Price to Sales (PS) ratio is 1.11. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OMCL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Omnicell Inc's stock?

In the past 10 years, Omnicell Inc has provided 0.005 (multiply by 100 for percentage) rate of return.